The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
The move will add new global talent to Cytel’s Strategic Consulting group
Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
To set up 50 lifestyle modification centres across the UAE in the next 24 months
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
Subscribe To Our Newsletter & Stay Updated
